Evaluation of IL 12B Genetic Polymorphism (rs3213094)
Recruiting · NCT07128472 · Interventional (participants receive a specific treatment) · Lead sponsor: South Valley University
View the official record on ClinicalTrials.gov →Interventions studied
Humira
What this trial is about
Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- \- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with psoriatic arthritis.
Exclusion criteria
- Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus).
- Pregnancy and lactation.
- Patients currently undergoing any treatment other than Humira.
- Patients with known genetic disorders affect immune system function.
- Patients were undergoing any treatment other than Humira in the last 6 months.
- Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV).
- Patients with contraindication to Humira.
- Renal \&Vascular diseases
Where it is running
1 location listed.
- Qina University hospital, South Valley University Hospital - Qina, Egypt